Comparison of treament regimens of kala-azar based on culture and sensitivity amastigotes to sodium antimony gluconate

Indian Journal of Medical Research

Volumn 127, Issue 6, 2008, Pages 582-588

  Thakur, C P ^a,b   Thakur, Shabnam ^a   Narayan, S ^a   Sinha, Arun ^a  

^a PATNA UNIVERSITY   (India)

^b NONE   (India)

Author keywords

Culture; Sensitivity of amastigotes; Sodium antimony gluconate; Treatment

Indexed keywords

AMPHOTERICIN B; ANTIMONY GLUCONATE; GLUCOSE; ANTIPROTOZOAL AGENT;

ADOLESCENT; ADULT; AGED; AMASTIGOTE; ARTICLE; BODY WEIGHT; BUTTOCK; CELL CULTURE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST OF ILLNESS; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG FATALITY; DRUG FEVER; DRUG SENSITIVITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HOSPITAL COST; HOSPITALIZATION; HUMAN; HUMAN CELL; INDIA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LEISHMANIASIS; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; PARASITE TRANSMISSION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SHIVERING; SIDE EFFECT; THROMBOPHLEBITIS; TREATMENT OUTCOME; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG RESISTANCE; GROWTH, DEVELOPMENT AND AGING; LEISHMANIA DONOVANI; MACROPHAGE; MIDDLE AGED; PARASITOLOGY; PRESCHOOL CHILD; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MALE; MIDDLE AGED;

EID: 51549111581     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Sen Gupta PC. Chemotherapy of leishmanial diseases, a resume of recent researches. Indian Med Gaz 1953; 88: 20-35.
2. Gupta PCS. Leishmaniasis. In: Banerjea, JC, Bhattacharya PB, editors. A handbook of tropical diseases, 6th ed. Kolkata: Academic Publishers; 1960. p. 103-40.
3. World Health Organization. The Leishmaniasis, Report of a WHO Expert Committee. Geneva: World Health Organization, Technical Report Series no. 701, 1984, p. 103.
4. Thakur CP. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including Post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 1984; 78: 391-8.
5. Thakur CP, Kumar M, Singh SK, Sharma D, Prasad US, Singh RSP, et al. Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Br Med J 1984; 288: 895-7.
6. Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. BMJ 1988; 296: 1557-61.
7. World Health Organization. Control of the Leishmaniasis WHO. Technical Report Series No 703. Geneva: WHO, 1990.
8. Peters W. The treatment of kala-azar: new approaches to an old problem. Indian J Med Res 1981; 73 (Suppl): 1-18.
9. Lira R, Sundar S, Makharia A, Kenny R, Gam A, Saraiva E, et al. Evidence that the high incidence of treatment failure in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999; 180: 564-7.
10. Thakur CP, Narayan S, Ranjan A. Epidemiological, clinical and pharmacological study of antimony resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 2004; 120: 166-72.
11. Veeken H, Ritmeijer R, Seaman J, Davidson R. A randomised comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmania'sis under field conditions in Sudan. Trop Med Int Health 2000; 5: 312-9.
12. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95: 668-72.
13. Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first line drug? An observational study of 80 cases. Ann Trop Med Parasitol 1998; 92: 561-9.
14. Thakur CP, Narayan S. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 2004; 98: 129-38.
15. Dowd JE. Health statistical methodology. In: de Raatd P, editor. Report of the workshop on the chemotherapy of mucocutanous leishmaniases. Geneva: World Health Organization; 1979. p. 17-19 (TDR/LEISH/MICL 79.3.).
16. Krolewiecki A, Leon S, Scott P, Abraham D. Activity of azithromycin against Leishmania major in vitro and in vivo. Am J Trop Med Hyg 2002; 67: 273-7.
17. Thakur CP, Sinha GP, Pandey AK. Comparison of regimens of amphotericin-B deoxycholate in kala-azar. Indian J Med Res 1996; 103: 259-63.
18. Thakur CP. Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin-B administration. Natl Med J India 1995; 8: 13-4.
19. Thakur CR Sodium antimony gluconate, amphotericin, and myocardial damage. Lancet 1998; 351: 1928-9.
20. Nuzum E, White F III, Thakur C, Dietze R, Wages J, Grogl M, et al. Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood. J Infect Dis 1995; 171: 751-4.
21. Berman JD, Chulay JD, Hendricks LD, Oster CN. Susceptibility of clinically sensitive and resistant leishmania to pentavalent antimony in vitro. Am J Trop Med Hyg 1982; 31: 459-65.
22. Chang KP. Human cutaneous Leishmania in a mouse macrophage line: propagation and isolation of intracellular parasites. Science 1980; 209: 240-2.
23. Hockmeyer WT, Kager PA, Rees PH, Hendricks LD. The culture of Leishmania donovani in Schneider's insect medium, its value in the diagnosis and management of patients with visceral leishmaniasis. Trans R Soc Trop Med Hyg 1981; 75: 861-6.
24. Hart DT, Vickerman K, Coombs GH. Transformation in vitro of Leishmania mexicana amastigotes to promastigotes: nutritional requirements and the effects of the drugs. Parasitology 1981; 83: 529-41.
25. Bhatnagar S, Guru PY, Katiyar JC, Srivastava R, Mukherjee A, Akhtar HS, et al. Exploration of antileishmanial activity in heterocycles, results of their in vivo and in vitro bio-evaluations. Indian J Med Res 1989; 89: 439-44.
26. Mbongo N, Loiseau PM, Billion MA, Robert-Gero M. Mechanisum of amphotericin B resistance in Leishmania donovani promastigotes. Antimcrob Agents Chemother 1998; 42: 352-7.
27. Hebeka EK, Solotorowsky M. Development of resistance to polyene antibiotics in Candida albicans. J Bacteriol 1965; 89: 11533-9.
28. Grogle M, Oduola AM, Cordero LD, Kyle DE. Leishmania spp: development of pentostam resistant clones in vitro by discontinuous drug exposure. Exp Parasitol 1989; 69: 78-90.
29. Thakur CP, Kumar A, Mitra G, Thakur S, Thakur M, Pharmacovigilance in kala-azar patients with severe thrombocytopenia caused by sodium antimony gluconate and miltefosine. Indian J Med Res 2007; 126: 73-5.
30. Bodhe PV, Kotwani RN, Kirodian BG, Pathare AV, Pandey AK, Thakur CP, et al. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1999; 93: 314-8.
31. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996; 90: 319-22.
32. Thakur CP. A single high dose treatment of kala-azar with Arnbisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 2001; 17: 67-70.
33. Sunder S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007; 356: 2571-81.